Cellular interferon-γ and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: action LADA 6.

Authors:
Address: Institute for Clinical Diabetology, German Diabetes Center at Heinrich-Heine-University, Leibniz Institute for Diabetes Research, Düsseldorf, Germany. alexander.strom@ddz.uni-duesseldorf.de
Journal:

Publication:

abstract

OBJECTIVE:

type 1 diabetes and latent autoimmune diabetes in adults (LADA) are thought to result from immune-mediated β-cell destruction. It remains unclear why LADA is clinically less severe compared to type 1 diabetes. This study aimed to compare the pro-inflammatory (interferon-γ, IFN-γ) and anti-inflammatory (interleukin-13, IL-13) T-cell responses in humans with LADA and type 1 diabetes.

RESEARCH DESIGN AND METHODS:

IFN-γ and IL-13 T-cell responses to a panel of 16 (auto)-antigens were tested using an enzyme linked immune-spot technique and peripheral T-cells from 35 patients with type 1 diabetes, 59 patients with type 2 diabetes, 23 LADA patients, and 42 control subjects.

RESULTS:

LADA and type 1 diabetes patients did not display any statistically significant differences in the frequency of IFN-γ or IL-13 responses to auto-antigenic stimuli, positive control or mitogen. Overall very low T cell reactivity to autoantigens was detected in all groups. IL-13 responses but not IFN-γ responses to recall antigen tetanus toxoid were higher in healthy control subjects compared to patients with type 1 or type 2 diabetes or LADA (P<0.05). Diabetes, independent of type, was associated with weaker response to recall antigen tetanus toxoid.

CONCLUSIONS:

LADA patients are indistinguishable from type 1 diabetes patients for Cellular IFN-γ and IL-13 responses upon mitogen and recall antigen stimulation. These results extend previous findings showing that systemic cytokine/chemokine and humoral responses in type 1 diabetes and LADA are similar.

Related Articles
Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes.
J Interferon Cytokine Res. 2004
Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes.
Tsiavou A, Degiannis D, Hatziagelaki E, Koniavitou K, Raptis SA. J Interferon Cytokine Res. 2004 Jul; 24(7):381-7.
Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Arthritis Res. 2000
Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L, Rönnelid J, Sanjeevi CB, Lampa J, Klareskog L. Arthritis Res. 2000; 2(1):75-84.
Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.
Diabetologia. 2011
Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.
Pham MN, Hawa MI, Pfleger C, Roden M, Schernthaner G, Pozzilli P, Buzzetti R, Scherbaum WA, Seissler J, Kolb H, et al. Diabetologia. 2011 Jul; 54(7):1630-8. Epub 2011 Feb 24.
Review Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Clin Ter. 2006
Review Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Clin Ter. 2006 Jul-Aug; 157(4):377-86.
Review Position statement. Part one: Immune function and exercise.
Exerc Immunol Rev. 2011
Review Position statement. Part one: Immune function and exercise.
Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, et al. Exerc Immunol Rev. 2011; 17:6-63.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.